Periodic Reporting for period 1 - BRIGHT (Treat severe cases of infection at COV with XAV-19)
Reporting period: 2020-08-01 to 2021-07-31
The company was able to demonstrate the strong interest of XAV-19 as potential candidate for treatment of COVID-19 in moderate patients. First of all, several samples of the product were obtained by immunizing donor animals for antibody production in our Belgian facility. The activity of XAV-19 as inhibitor of the different forms of virus, including variants of concern, was demonstrated. In parallel, in vivo activity was shown in mice in collaboration with the excellent team of Pasteur Institute in Hong Kong, China.
Once the preclinical proof of concept was established the company was able to produce batches compliant with the pharmaceutical good manufacturing practices, demonstrate preclinical safety and initiating a clinical trial offering hope to patients suffering from moderate COVID-19. The clinical trial EUROXAV is currently recruiting in Greece, Romania and Bulgaria, and Spain.
The EU support has allowed the SME XENOTHERA to publish 4 original scientific papers on COVID-19 and to raise 20M€ in equity since last August 2020.